Cx Institutional Fate Therapeutics Inc Transaction History
Cx Institutional
- $3.29 Billion
- Q3 2025
A detailed history of Cx Institutional transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Cx Institutional holds 2,817 shares of FATE stock, worth $3,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,817Holding current value
$3,549% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
154Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$16.2 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$11 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$5.73 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$4.28 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $122M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...